Under the agreement, Incyte will retain responsibility for the manufacturing and development of the treatment. Specialised Therapeutics, based in Singapore, will oversee the regulatory submissions, medical affairs, and local distribution. CEO Carlo Montagner described the move as a strategic entry into the inflammatory dermatology sector, noting that the firm will now begin navigating Australian reimbursement and regulatory pathways to facilitate patient access.
Lee Heeson, Executive Vice President at Incyte, stated that the collaboration leverages the partner's proven experience in handling complex commercial environments within the region. While the timeline for local availability remains subject to healthcare authority approval, the deal marks a significant step in expanding the reach of the JAK1/JAK2 inhibitor, which has already been used by over one million patients globally.
Comments (0)
No comments yet. Be the first!